Want to see SE:FLUO full AI Analyst Report?

FluoGuide A/S (FLUO) Price & Analysis

1 Followers

FLUO Stock Chart & Stats

kr36.00

-kr1.70(-3.82%)

At close: Mar 06 4:00 PM EST

kr36.00

-kr1.70(-3.82%)

Day’s Range― - ―

52-Week Rangekr28.00 - kr47.80

Previous CloseN/A

Volume5.01K

Average Volume (3M)8.21K

Market Cap

kr524.81M

Enterprise Valuekr427.89M

Total Cash (Recent Filing)kr63.24M

Total Debt (Recent Filing)kr27.93M

Price to Earnings (P/E)―

Beta0.34

Next Earnings

Aug 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.89

Shares Outstanding16,349,314

10 Day Avg. Volume11,579

30 Day Avg. Volume8,206

Financial Highlights & Ratios

PEG Ratio-0.29

Price to Book (P/B)6.10

Price to Sales (P/S)0.00

P/FCF Ratio-8.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.98

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Niche Surgical Imaging FocusFluoGuide’s specialization in fluorescence-guided surgical imaging addresses a durable clinical need in oncology for better intraoperative tumor visualization. Focused technology and clinical development create high technical barriers and potential for sustained adoption if clinical outcomes and approvals are achieved.

Positive Equity And Moderate LeverageReported positive equity (~43.1m) and modest debt/equity (~0.52x) provide structural financial flexibility. Manageable leverage reduces near-term solvency risk and supports continued R&D and clinical programs, offering a firmer runway to advance assets before large-scale commercialization.

Improving Cash-flow TrendFree cash flow burn has improved versus the prior annual period, indicating operational progress or cost control. While still negative, an improving cash-flow trend is a durable positive as it extends runway, reduces reliance on external financing, and increases the chance of reaching value-driving clinical milestones.

Bears Say

Sustained High Cash BurnMaterial TTM operating outflows (~-42.1m) and free cash flow (~-37.5m) reflect structural cash consumption. Persistent large burn depletes equity, forces repeated external financing rounds that can be dilutive, and constrains multi-year clinical development and commercialization without sustained revenue.

Minimal And Volatile RevenueRevenue collapsed to zero in the latest annual period and TTM receipts are negligible, signaling no consistent commercial traction. This structural lack of recurring revenue makes the business dependent on external capital or milestone receipts and increases risk to long-term viability absent product adoption.

Deep Operating LossesOperating losses materially exceed sales and profitability remains deeply negative. Sustained negative margins erode shareholder equity, impair ability to invest in commercialization or trials, and limit strategic options unless unit economics or revenue scale improve meaningfully.

FluoGuide A/S News

FluoGuide’s FG001 Phase 2 Trial Targets Sharper Brain Tumor Surgery and New Value for Investors

FluoGuide A/S ($SE:FLUO) announced an update on their ongoing clinical study. FluoGuide A/S (FLUO) is launching a Phase...

2M ago

FLUO

FLUO FAQ

What was FluoGuide A/S’s price range in the past 12 months?

FluoGuide A/S lowest stock price was kr28.00 and its highest was kr47.80 in the past 12 months.

What is FluoGuide A/S’s market cap?

FluoGuide A/S’s market cap is kr524.81M.

When is FluoGuide A/S’s upcoming earnings report date?

FluoGuide A/S’s upcoming earnings report date is Aug 25, 2026 which is in 32 days.

How were FluoGuide A/S’s earnings last quarter?

FluoGuide A/S released its earnings results on May 27, 2026. The company reported -kr1.032 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.032.

Is FluoGuide A/S overvalued?

According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FluoGuide A/S pay dividends?

FluoGuide A/S does not currently pay dividends.

What is FluoGuide A/S’s EPS estimate?

FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FluoGuide A/S have?

FluoGuide A/S has 16,349,314 shares outstanding.

What happened to FluoGuide A/S’s price movement after its last earnings report?

FluoGuide A/S reported an EPS of -kr1.032 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.687%.

Which hedge fund is a major shareholder of FluoGuide A/S?

Currently, no hedge funds are holding shares in SE:FLUO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FluoGuide A/S

FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.